$1.76
-0.07 (-3.56%)
Open$1.84
Previous Close$1.83
Day High$1.84
Day Low$1.75
52W High$5.48
52W Low$1.68
Volume—
Avg Volume1.09M
Market Cap112.20M
P/E Ratio—
EPS$-1.81
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+2,538.6% upside
Current
$1.76
$1.76
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 44.87M | 45.07M | 42.57M |
| Net Income | -133,063,981 | -120,274,764 | -129,666 |
| Profit Margin | -296.5% | -281.7% | -0.3% |
| EBITDA | -142,027,110 | -135,508,440 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | -0.4% | -0.4% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |